Global Neuroblastoma Research Report: Information by Diagnostics (MIBG Scan and Biopsy), by Treatment (Surgical), and by End User (Hospitals and Others)—Forecast till 2027

Neuroblastoma Market Scenario

The neuroblastoma market is expected to grow steadily over the forecast period. It is projected that the market held a market value of USD 2.60 billion in 2016 and is projected to grow at a CAGR of 3.7% over the forecast period. Neuroblastoma is a common cancer detected in infants. Neuroblastoma develops from immature nerve cells found in various parts of the body. It most commonly occurs in children or young ones below 5 years old. The patient having neuroblastoma may cause symptoms such as backbone pain, weight loss, abdominal pain, enlarged stomach, bulging eyes, weight, crankiness, anemia, fever, bone pain, dark circles around the eyes, weakness, high blood pressure, and constipation or diarrhea. 

The factors such as a mutation in germline cells, change in lifestyle and family history of neuroblastoma may cause this disease. In some cases, it may cause due to the use of fertility drugs, maternal use of hair dye, infection, and, atopy. According to the American Childhood Cancer Organization and the International Agency for Research on Cancer (IARC) 2016 report release, it was estimated that approximately 80,000 deaths are caused by childhood cancer globally. Such an increasing case of childhood cancer every year may support this market positively. However, due to the late effects associated with neuroblastoma treatment such as loss of some organ function or hearing loss and others may restrain the neuroblastoma market growth. Also, the high cost of this therapy over the conventional treatment or side effects associated with the treatment can hamper the market growth. Also, the dearth of skilled healthcare professionals can hamper the market growth over the forecast period.

Segmentation

The neuroblastoma market has been segmented into diagnostics, treatment, and end user.

The market, on the basis of diagnostics, has been segmented into various tests, MIBG scan, imaging, and biopsy. The tests are further sub-segmented into bone marrow, tissue, urine, and blood.

The market, by treatment, has been segmented into surgery, chemotherapy, radiation therapy, stem cell transplant, immunotherapy, and monoclonal antibody treatment. The market, by end user, has been segmented into hospitals ambulatory surgical centers, diagnostic centers, research centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The neuroblastoma market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European neuroblastoma market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The neuroblastoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The neuroblastoma market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

United Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc., and others are some of the key players in the global neuroblastoma market.

Regional Market Summary

Global Neuroblastoma Market Share (%), by Region, 2017

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports

Geographically, the Americas is predicted to dominate the global neuroblastoma market owing to a well-developed healthcare sector and growing incidences of childhood cancer. According to the American Society of Clinical Oncology (ASCO) in April 2018, article neuroblastoma accounts for 6% of all childhood cancers in the US. It was also indicated that it is the third most common type of cancer in infants. This influences the market growth in North America.

Europe is likely to hold the second largest position in the global neuroblastoma market. The market growth in this region is attributed to the increasing number of infant’s cancer with developed healthcare infrastructure.  According to the Cancer Research UK May 2016, statistics 1,821 new cases of children's cancer was listed in 2013-2015, in the UK. The increase in cases of childhood cancer in this region supports this market growth.

The neuroblastoma market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is predictable to be the fastest growing region due to the enormous patient population of childhood cancer and increasing development of hospitals for childhood cancer treatment in the Asia-Pacific region.

The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.

Global Neuroblastoma Market, by Diagnostics

• Tests


• Bone Marrow Testing


• Tissue Testing


• Urine and Blood Testing


• MIBG Scan


• Imaging


• Biopsy

Global Neuroblastoma Market, by Treatment

• Medications


• Surgery


• Chemotherapy


• Radiation therapy


• Stem Cell Transplant


• Immunotherapy


• Monoclonal antibody treatment

Global Neuroblastoma Market, by End User

• Hospitals and clinics


• Ambulatory Surgical Centers


• Diagnostic Centers


• Research centers


• Others

Global Neuroblastoma Market, by Region

Americas

• North America


• US


• Canada


• South America

Europe

• Western Europe


• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe


• Eastern Europe

Asia-Pacific

• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific

Middle East & Africa

• Middle East


• Africa

Global Neuroblastoma Market, by Key Players

United Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc., and others are some of the key players in the global neuroblastoma market.

Intended Audience

• Manufacturers and vendors


• Research associations related to  cancer in children


• Hospitals and clinics


• Various research and consulting firms